Objective: This Phase II study was conducted to evaluate the effects of irinotecan plus capecitabine in patients with advanced gastric cancer (AGC) who had received a first-line therapy of 5-fluorouracil/platinum regimen. Methods: Patients received capecitabine 1000 mg/m 2 b.i.d. on days 1 -14 followed by a 7-day rest period, and irinotecan 100 mg/m 2 was administered through a 90 min intravenous infusion on days 1 and 8, based on a 3-week cycle. Results: Forty-six (95.8%) of the 48 patients were assessable for response. Thirteen cases of partial response were confirmed, response rate of 27.1% (95% CI, 14.5 -39.7%). The median follow-up period was 25.2 months. The median time to progression and overall survival for all patients were 4.1 months (95% CI, 3.4 -4.8 months) and 7.6 months (95% CI, 5.1 -10.1 months). Grade 3 diarrhea and hand-foot syndrome occurred in eight (17.4%) and two (4.3%) patients, respectively. The most common Grade 3/4 hematological adverse event was neutropenia in four (8.7%) patients. There were no treatment-related deaths during this study. Conclusion: Irinotecan plus capecitabine was a relatively active and tolerable regimen as a second-line chemotherapy for AGC. Further investigation of this regimen is warranted, including the addition of new biological agents such as bevacizumab or cetuximab to improve the salvage regimen.
INTRODUCTION
Globally, gastric cancer is the second most common cause of cancer-related mortality, with over 700 000 attributable deaths reported in 2002 (1) . Although there are wide geographical variations in incidence, with peak age-standardized rates reported for East Asia (Japan and China), it has been estimated that this disease caused in excess of 188 000 deaths in Europe alone in 2006 (2) . Gastric cancer is often diagnosed at an advanced stage, with approximately half of all patients presenting with unresectable, locally advanced or metastatic disease.
Numerous classical chemotherapy agents, including 5-fluorouracil (5-FU), methotrexate (MTX), mitomycin-C, doxorubicin, cisplatinum, etoposide and epirubicin, have shown clinical activity in advanced gastric cancer (AGC). Among them, 5-FU and cisplatinum have been widely used as a component of combination therapy such as in the widely used ECF regimen (epirubicin, cisplatinum and 5-FU). Therapy with ECF is associated with significant benefits in terms of response rate (RR) and survival in patients with AGC compared with FAMTX (5-FU, adriamycin and high-dose MTX) chemotherapy in randomized Phase III studies (3, 4) . In addition, randomized trials have shown that the combination of 5-FU and cisplatinum is associated with improved RR and time to progression (TTP) compared with FAM (5-FU, doxorubicin and mitomycin) or 5-FU monotherapy (5) . Unfortunately, nearly half of all AGC patients will not respond to cisplatinum-based first-line chemotherapy. Furthermore, most patients who achieve response to the first-line chemotherapy will ultimately experience clinical disease progression and require second-line treatment. There is a pressing need for effective salvage treatment after the failure of first-line chemotherapy in AGC.
Irinotecan (Camptor w ; Pfizer) is a semisynthetic plant alkaloid camptothecin, which inhibits DNA topoisomerase-I. SN-38 has been identified to be the important metabolite of irinotecan, and to inhibit the regulation of DNA during cell replication. In recent meta-analysis of chemotherapies used to treat AGC, a comparison between irinotecan-containing versus non-irinotecan-containing combinations (mainly 5-FU/cisplatin) showed a non-survival benefit in favor of irinotecan-containing regimens (HR ¼ 0.88) (6) . Capecitabine (Xeloda w ; Roche) is an oral fluoropyrimidine that selectively generates higher levels of 5-FU in cancer tissues than in normal tissues via the action of thymidine phosphorylase. Capecitabine monotherapy was proved to be active against AGC with the RR ranged from 19.4% to 34%; moreover, median survival duration in these studies was comparable to other double or triple combination chemotherapies (7, 8) . In addition, in preclinical xenograft models, capecitabine was highly active against both 5-FU-sensitive and -resistant tumors (9) .
Irinotecan and capecitabine in combination could be possible to have a synergistic effect in previous pre-clinical and clinical studies (10 -14) . Irinotecan reduces DNA synthesis, increases dTTP pools and inhibits dUMP synthesis, which are also associated with the anti-tumor activity of capecitabine (11) . Actually, irinotecan/capecitabine combination regimens have been used to treat several types of solid tumors (15 -18) . On the basis of these promising results, we conducted this Phase II study to evaluate the effects of irinotecan plus capecitabine in patients with AGC who had received a first-line therapy of 5-FU/platinum regimen.
PATIENTS AND METHODS

ELIGIBILITY CRITERIA
All the patients involved in the current study had histologically confirmed metastatic or recurrent gastric adenocarcinoma with at least one unidimensionally measurable lesion (i.e. a diameter !1 cm, as assessed by spiral computed tomography). The patients were 18 -75 years of age with a performance status of 0 -2 on the Eastern Cooperative Oncology Group (ECOG) scale. Plus, adequate hematological (absolute neutrophil count !1.5 Â 10 9 /l, platelet count !100 Â 10 9 /l and hemoglobin !9 g/dl), renal (serum creatinine 1.5 mg/dl and creatinine clearance !50 ml/min) and hepatic (total bilirubin 2.0 mg/dl and serum transaminase level 3 times the upper limit of the normal range) levels were also required, and prior exposure and failure to a combination of 5-FU and platinum (cisplatin, heptaplatin or oxaliplatin) chemotherapy. Exclusion criteria included: gastric or esophageal cancer other than adenocarcinoma; central nervous system metastases; unresolved bowel obstruction or sub-obstruction; chronic diarrhea; other serious medical conditions (unstable cardiac disease requiring treatment); uncontrolled angina pectoris; myocardial infarction within 6 months; active uncontrolled infections, uncontrolled diabetes with symptomatic peripheral neuropathy); any history of anaphylaxis to drugs; and history of other cancer within the past 5 years, except for curatively treated non-melanoma skin cancer or in situ carcinoma of the cervix. The institutional review board of author's institution approved the protocol, and written informed consent was obtained from all patients before enrollment.
STUDY TREATMENT
All the treatments were administered on an outpatient basis. Capecitabine 1000 mg/m 2 b.i.d. with pyridoxine 100 mg t.i.d. was given on days 1 -14 followed by a 7-day rest period. The capecitabine was supplied as film-coated tablets at two dose strengths, 150 and 500 mg, whereas the irinotecan 100 mg/m 2 was administered through a 90 min intravenous infusion on days 1 and 8, based on a 3-week cycle. The dose schedule of this study was based on the early encouraging results from Phase I/II trials evaluating XELIRI/CAPIRI regimens (capecitabine at 1000 mg/m 2 for 2 weeks plus irinotecan at 240 -250 mg/m 2 on day 1 or 80 -100 mg/m 2 on days 1 and 8) (19 -22) . All patients received 5-HT3 inhibitors for emesis prophylaxis. Treatment continued until disease progression or intolerable toxicity. Patients who achieved a complete response (CR) could receive an additional two cycles of treatment at the investigator's discretion. Doses were recalculated before each cycle and adjusted as needed.
DOSE MODIFICATION
A physical examination was carried out before each cycle of therapy. Complete blood counts and biochemical tests were performed before each cycle. Safety was evaluated before each treatment cycle according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC), version 2.0. Hand-foot syndrome (HFS) was graded as described previously (23) . Patients were required to meet all of the following criteria to begin the next cycle of treatment: neutrophil count !1.5 Â 10 9 /l; platelet count !100 Â 10 9 /l and resolution or improvement of clinically significant non-hematologic adverse events to Grade 1 or 0. Patients were excluded if treatment was delayed for 2 weeks. Dosage modification could be made on day 1 of a new cycle (on the basis of laboratory values obtained on that day and the adverse events encountered during the preceding cycle). Safety assessment and dose adjustments of capecitabine for HFS were as follows: no reductions for Grade 1; a 25% reduction for Grade 2 and a 50% reduction for Grade 3 HFS.
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Any patient who required more than a 50% dose reduction was withdrawn from the study.
RESPONSE TO TREATMENT AND ADVERSE EFFECTS
The primary endpoint of this study was RR, and secondary endpoints were toxicity, TTP and overall survival (OS). Before entering the study, all patients received physical examination, full blood count and serum chemistry analyses. Chest X-ray, ECG, upper gastrointestinal endoscopies, abdominal computer tomographic (CT) scans and other appropriate procedures were also performed as needed. After every two cycles of treatment, response was evaluated using RECIST criteria. Of the lesions observed prior to treatment, a maximum of five measurable lesions from each metastasized organ up to a total of 10 lesions were selected as target lesions. In cases of partial response (PR) or CR, a confirmative CT scan was performed 4 weeks later and this was followed by a CT scan after every two treatment cycles. Toxicity was graded according to Version 2.0 of the National Cancer Institute-Common Toxicity Criteria (NCI-CTC). Tumor-related symptoms were assessed at baseline and before each cycle.
STATISTICAL ANALYSIS
The current trial used a two-stage optimal design, as proposed by Simon (24) , with an 80% power to accept the hypothesis and 5% significance to reject the hypothesis. According to the published data of RR of 16.3 -24% from most second-line chemotherapy trials in patients with AGC refractory to fluoropyrimidine and/or platinum (25 -27) , the current trial was designed to detect an RR of 40% when compared with a minimal, clinically meaningful RR of 20%. Allowing for a follow-up loss rate of 10%, the total sample size was 48 patients with a measurable disease. All enrolled patients were included in the intention-to-treat analysis of efficacy. The duration of response, TTP and survival analyses were all estimated using the Kaplan -Meier method. The duration of response was defined as the interval from the onset of a CR or PR until evidence of disease progression was found. Meanwhile, the TTP was calculated from the initiation of chemotherapy to the date of disease progression, whereas OS was measured from the initiation of chemotherapy to the date of the last follow-up or death. The statistical data were obtained using an SPSS software package (SPSS 11.5 Inc., Chicago, IL, USA).
RESULTS
PATIENT CHARACTERISTICS
From June 2005 to July 2007, a total of 48 patients were enrolled in the current study. The characteristics of the patients are summarized in Table 3 . Most patients experienced neutropenia during their course of therapy with 6.5% of patients (n ¼ 3) for Grade 3 and 2.2% (n ¼ 1) for Grade 4 neutropenia. Grade 1 or 2 neutropenia was detected in 56.5% of patients (n ¼ 26). Grade 3 febrile neutropenia were documented in two (4.3%) patients. Nausea, vomiting, diarrhea and HFS were the most common non-hematological toxicities. Grade 3 nausea, vomiting, diarrhea and HFS were observed in one (2.2%), two (4.3%), eight (17.4%) and two (4.3%) patients, respectively. However, no Grade 4 non-hematologic toxicity was observed in this study. Grade 1 or 2 nausea, diarrhea and HFS were detected in 34 (73.9%), 21 (45.7%) and 25 (54.3%) patients, respectively. No patients were discontinued from the study due to toxic effects. There were no treatment-related deaths during this study.
DISCUSSION
Unresectable advanced or metastatic gastric cancer still has a poor prognosis, with a median survival of just 7 -10 months. Several combinations regimens of chemotherapy have been developed, but the survival advantage appears to be marginal, and no worldwide standard regimens have as yet been established. Recent meta-analysis has been carried out to assess the efficacy and tolerability of chemotherapy in patients with AGC. Analysis of chemotherapy versus best supportive care (HR ¼ 0.39, 95% CI 0.28 -0.52) and combination versus single agent, mainly 5-FU (HR ¼ 0.83, 95% CI 0.74 -0.93), demonstrated significant OS results in favor of chemotherapy and combination chemotherapy (6) . However, most patients receiving first-line chemotherapy Figure 1 . Time to disease progression and overall survival for all patients. eventually develop progressive disease, whereas there is no established second-line regimen.
In this study, we found that irinotecan plus capecitabine was an active and safe salvage chemotherapy when used in routine clinical practice for patients with AGC for whom 5-FU and platinum-based first-line chemotherapy had previously failed. This study demonstrated that capecitabine 1000 mg/m 2 b.i.d. on days 1 -14 followed by a 7-day rest period, and irinotecan 100 mg/m 2 was administered through a 90 min intravenous infusion on days 1 and 8, based on a 3-week cycle, was active and well tolerated as a second-line therapy in pretreated patients with AGC. The overall RR was 27.1%, and median TTP and OS were 4.1 and 7.6 months, respectively. In the current study, the efficacy was comparable to the published data from most second-line chemotherapy for patients with AGC refractory to fluoropyrimidine and/or platinum. Taguchi (25) , Vanhoefer (26) and Lee et al. (27) , respectively, reported a 24% RR with docetaxel 60 mg/m 2 in 59 patients, a 20% RR with docetaxel 100 mg/m 2 in 25 patients and a 16.3% RR with docetaxel 75 mg/m 2 in 49 patients who had already been exposed to first-line 5-FU and cisplatin, respectively.
In the current study, overall, the treatment was well tolerated. A Phase II study by Kim et al. (28) reported that a capecitabine plus cisplatin regimen produced a high RR of 54.8% and median OS of 10.1 months in patients with AGC. In contrast, the current study used a reduced dose of capecitabine, 1000 mg/m 2 instead of 1250 mg/m 2 , owing to the relatively high incidence of HFS. Grade 2/3 HFS has previously been observed in 27.5 -50% of patients with AGC who received the standard dose of capecitabine (28, 29) , and as there is no effective prophylaxis or treatment for HFS, this can interrupt treatment or reduce the dose intensity of capecitabine. In the current study, only six patients (13.0%) experienced Grade 2/3 HFS.
The major toxicities related to irinotecan are diarrhea and myelosuppression, which are known to be dose dependent. Chemotherapy-induced severe diarrhea or neutropenia can also result in treatment-related hospitalization or mortality, thereby compromising the quality of life and increasing medical expenditure. In a randomized multicenter Phase II trial comparing two different schedules of irinotecan combined with capecitabine as the first-line treatment for metastatic colorectal cancer (30) , diarrhea, which occurred in 37.8% of the patients at a Grade 3/4 intensity, was the main adverse effect of the arm B regimen (capecitabine 1000 mg/m 2 twice daily on days 2 -15 and irinotecan 120 mg/m 2 on days 1 and 8, every 21 days). However, in the present study, a reduced dose of irinotecan (100 mg/m 2 on days 1 and 8) was administered to alleviate adverse effects, and Grade 3/4 diarrhea and neutropenia were only observed in 17.4% and 6.5% of the patients, respectively, which are consistent with previous findings (18) . No patients were discontinued from the study due to toxic effects. Furthermore, there was no treatment-related death or Grade 4 nonhematological adverse events in the current study.
In conclusion, irinotecan plus capecitabine was a relatively active and tolerable regimen as a second-line chemotherapy for AGC. Further investigation of this regimen is warranted, including the addition of new biological agents such as bevacizumab or cetuximab to improve the salvage regimen.
